Evolution of sodium glucose co-transporter 2 inhibitors as anti-diabetic agents

Inhibition of Renal Glucose Reabsorption: A Novel Strategy for Achieving Glucose Control in Type 2 Diabetes Mellitus

(2013) Muhammad Abdul-Ghani et al.   Endocrine Practice

Dapagliflozin: an emerging treatment option in type 2 diabetes

(2009) Mark Kipnes   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Development of the Renal Glucose Reabsorption Inhibitors: A New Mechanism for the Pharmacotherapy of Diabetes Mellitus Type 2

(2009) William N. Washburn   JOURNAL OF MEDICINAL CHEMISTRY

Dapagliflozin, a Selective SGLT2 Inhibitor, Improves Glucose Homeostasis in Normal and Diabetic Rats

(2008) S. Han et al.   DIABETES

Sodium-Glucose Cotransport Inhibition With Dapagliflozin in Type 2 Diabetes

(2008) J. F. List et al.   DIABETES CARE

Sodium glucose co-transporter 2 inhibitors: blocking renal tubular reabsorption of glucose to improve glycaemic control in patients with diabetes

(2008) S. A. Jabbour et al.   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

Discovery of Dapagliflozin: A Potent, Selective Renal Sodium-Dependent Glucose Cotransporter 2 (SGLT2) Inhibitor for the Treatment of Type 2 Diabetes

(2008) Wei Meng et al.   JOURNAL OF MEDICINAL CHEMISTRY